Waaler A, Jørgensen N P, Koksvik B, Skinnemoen K, Andrew E
Clinical Department, Nycomed AS, Oslo, Norway.
Acta Radiol Suppl. 1987;370:113-7.
Iopentol is a new non-ionic contrast medium. In order to study the pharmacokinetic properties, iopentol 350 mg I/ml was administered intravenously to healthy male volunteers at 3 dose levels (0.3, 0.6 and 1.2 g I/kg body weight). To evaluate renal excretion all subjects were given chromium-51-ethylenediaminetetraacetic acid (51Cr-EDTA) additionally to iopentol. The highest dose level group also received saline and 51Cr-EDTA about 3 weeks prior to iopentol. Serum, urine and faeces were sampled at different time intervals. Unmetabolized iopentol was excreted almost entirely in urine during the first 24 hours by means of glomerular filtration. A small fraction (2%) of the dose was excreted in faeces. No dose dependent pharmacokinetics was observed up to doses of 1.2 g I/kg body weight. The pharmacokinetic properties of iopentol make it a well suited contrast medium for vascular use.
碘海醇是一种新型非离子型造影剂。为研究其药代动力学特性,将350mg I/ml的碘海醇以3种剂量水平(0.3、0.6和1.2g I/kg体重)静脉注射给健康男性志愿者。为评估肾脏排泄情况,所有受试者在接受碘海醇的同时还额外给予了铬-51-乙二胺四乙酸(51Cr-EDTA)。最高剂量水平组在注射碘海醇约3周前还接受了生理盐水和51Cr-EDTA。在不同时间间隔采集血清、尿液和粪便样本。未代谢的碘海醇在最初24小时内几乎完全通过肾小球滤过经尿液排出。一小部分(2%)剂量经粪便排出。在剂量高达1.2g I/kg体重时未观察到剂量依赖性药代动力学。碘海醇的药代动力学特性使其成为一种非常适合血管造影使用的造影剂。